6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
* O
Most O
of O
the O
safety O
experience O
is O
with O
sevelamer O
tablets O
and O
sevelamer O
hydrochloride O
. O

In O
long-term O
studies O
with O
sevelamer O
hydrochloride O
, O
which O
contains O
the O
same O
active O
moiety O
as O
sevelamer O
carbonate O
, O
the O
most O
common O
adverse O
events O
included O
: O
vomiting O
( O
22 O
% O
) O
, O
nausea O
( O
20 O
% O
) O
, O
diarrhea O
( O
19 O
% O
) O
, O
dyspepsia O
( O
16 O
% O
) O
, O
abdominal O
pain O
( O
9 O
% O
) O
, O
flatulence O
( O
8 O
% O
) O
, O
and O
constipation O
( O
8 O
% O
) O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Genzyme O
Corporation O
at O
1-800-847-0069 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

There O
are O
limited O
clinical O
trial O
data O
on O
the O
safety O
of O
Renvela O
. O

However O
, O
because O
it O
contains O
the O
same O
active O
ingredient O
as O
the O
hydrochloride O
salt O
, O
the O
adverse O
event O
profiles O
of O
the O
two O
salts O
are O
expected O
to O
be O
similar O
. O

In O
a O
cross-over O
study O
in O
hemodialysis O
patients O
with O
treatment O
durations O
of O
eight O
weeks O
each O
and O
no O
washout O
, O
and O
another O
cross-over O
study O
in O
hemodialysis O
patients O
with O
treatment O
durations O
of O
four O
weeks O
each O
and O
no O
washout O
between O
treatment O
periods O
, O
the O
adverse O
reactions O
on O
sevelamer O
carbonate O
powder O
were O
similar O
to O
those O
reported O
for O
sevelamer O
hydrochloride O
. O

In O
a O
parallel O
design O
study O
of O
sevelamer O
hydrochloride O
with O
treatment O
duration O
of O
52 O
weeks O
, O
adverse O
reactions O
reported O
for O
sevelamer O
hydrochloride O
( O
n=99 O
) O
were O
similar O
to O
those O
reported O
for O
the O
active-comparator O
group O
( O
n=101 O
) O
. O

Overall O
adverse O
reactions O
among O
those O
treated O
with O
sevelamer O
hydrochloride O
occurring O
in O
> O
5 O
% O
of O
patients O
included O
: O
vomiting B-OSE_Labeled_AE
( O
22 O
% O
) O
, O
nausea B-OSE_Labeled_AE
( O
20 O
% O
) O
, O
diarrhea B-OSE_Labeled_AE
( O
19 O
% O
) O
, O
dyspepsia B-OSE_Labeled_AE
( O
16 O
% O
) O
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
9 O
% O
) O
, O
flatulence B-OSE_Labeled_AE
( O
8 O
% O
) O
, O
and O
constipation B-OSE_Labeled_AE
( O
8 O
% O
) O
. O

A O
total O
of O
27 O
patients O
treated O
with O
sevelamer O
and O
10 O
patients O
treated O
with O
comparator O
withdrew O
from O
the O
study O
due O
to O
adverse O
reactions O
. O

Based O
on O
studies O
of O
8-52 O
weeks O
, O
the O
most O
common O
reason O
for O
withdrawal O
from O
sevelamer O
hydrochloride O
was O
gastrointestinal B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
3 O
% O
-16 O
% O
) O
. O

In O
143 O
peritoneal O
dialysis O
patients O
studied O
for O
12 O
weeks O
using O
sevelamer O
hydrochloride O
, O
most O
common O
adverse O
reactions O
were O
similar O
to O
adverse O
reactions O
observed O
in O
hemodialysis O
patients O
. O

The O
most O
frequently O
occurring O
treatment O
emergent O
serious O
adverse O
reaction O
was O
peritonitis B-OSE_Labeled_AE
( O
8 O
reactions O
in O
8 O
patients O
[ O
8 O
% O
] O
in O
the O
sevelamer O
group O
and O
2 O
reactions O
in O
2 O
patients O
[ O
4 O
% O
] O
on O
active O
control O
) O
. O

Thirteen O
patients O
( O
14 O
% O
) O
in O
the O
sevelamer O
group O
and O
9 O
patients O
( O
20 O
% O
) O
in O
the O
active-control O
group O
discontinued O
, O
mostly O
for O
gastrointestinal B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

6.2 O
Postmarketing O
Experience O
Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
to O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

The O
following O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
sevelamer O
hydrochloride O
or O
sevelamer O
carbonate O
: O
hypersensitivity B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
fecal B-OSE_Labeled_AE
impaction I-OSE_Labeled_AE
, O
and O
uncommon O
cases O
of O
ileus B-OSE_Labeled_AE
, O
intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
, O
and O
intestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
. O

Appropriate O
medical O
management O
should O
be O
given O
to O
patients O
who O
develop O
constipation B-NonOSE_AE
or O
have O
worsening O
of O
existing O
constipation B-NonOSE_AE
to O
avoid O
severe O
complications O
. O

